Small molecular inhibitors of RAD51 recombinase and methods thereof
View Patent ↗The invention includes compositions comprising a selective small-molecule inhibitor of RAD51 recombinase and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention.
1. A method of treating a RAD51-overexpressing cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a pharmaceutically effective amount of at least one compound selected from the group consisting of Formula (1), Formula (2), Formula (3), a salt thereof, and any combinations thereof:
wherein in (1):
R 1 is pyridinyl,
R 2 is selected from the group consisting of C 1 -C 6 alkyl, —(C 1 -C 6 )alkylene-phenyl, and —(C 1 -C 6 )alkylene-phenyl wherein the phenyl is substituted with a C 1 -C 6 alkyl; and
R 3 is H;
the method further comprising administering to the subject a treatment selected from the group consisting of (i) radiation therapy, and (ii) a pharmaceutically effective amount of a chemotherapeutic agent.
2. The method of claim 1 , wherein the at least one compound is selected from the group consisting of (E)-3-benzyl-2-(2-(pyridin-3-yl)vinyl)quinazolin-4(3H)-one (1a), (E)-3-ethyl-2-(2-(pyridin-3-yl)vinyl)quinazolin-4(3H)-one (1b), (E)-2-(2-(pyridin-3-yl)vinyl)-3-(m-tolyl)quinazolin-4(3H)-one (1c), 1,4,10-trihydroxy-5-(hydroxymethyl)-8-methyl-3,7-dioxo-3,7-dihydro-1H-benzo[6,7][1,4]dioxepino[2,3-e]isobenzofuran-11-carbaldehyde (2), 1,4-dihydroxy-10-methoxy-5,8-dimethyl-3,7-dioxo-3,7-dihydro-1H-benzo[6,7][1,4] dioxepino[2,3-e]isobenzofuran-11-carbaldehyde (3), a salt thereof, and mixtures thereof.
3. The method of claim 1 , wherein administering to the subject of the composition is performed at least 24 hours prior to administering to the subject the radiation therapy or the chemotherapeutic agent.
4. The method of claim 3 , wherein administering to the subject of the composition is performed at least 12 hours prior to administering to the subject the radiation therapy or the chemotherapeutic agent.
5. The method of claim 4 , wherein administering to the subject of the composition is performed at least 6 hours prior to administering to the subject the radiation therapy or the chemotherapeutic agent.
6. The method of claim 5 , wherein administering to the subject of the composition is performed at least 3 hours prior to administering to the subject the radiation therapy or the chemotherapeutic agent.
7. The method of claim 6 , wherein administering to the subject of the composition is performed at least 1 hour prior to administering to the subject the radiation therapy or the chemotherapeutic agent.
8. The method of claim 1 , wherein the composition is co-administered to the subject with the radiation therapy or the chemotherapeutic agent.
9. The method of claim 8 , wherein the composition and the chemotherapeutic agent are co-formulated.
10. The method of claim 1 , wherein the subject is a human.